An overview of 3 clinical trials of an investigational gene therapy for the treatment of AADC is provided in this infographic, distributed at the PTC Therapeutics symposium at CNS 2021
The PTC Therapeutics symposium at CNS 2021 presents different clinical perspectives and experiences of an investigational gene therapy for the treatment of AADC deficiency
Change in the duration and frequency of oculogyric crises (OGC) in children with AADC deficiency following treatment with eladocagene exuparvovec, an investigational gene therapy, are presented in this poster from the 2021 CNS Annual Meeting
Changes in motor scale scores in children with AADC deficiency following treatment with eladocagene exuparvovec, an investigational gene therapy, are presented in this poster from the 2021 CNS Annual Meeting
Changes in body weight and rate of respiratory infections in children with AADC deficiency following treatment with eladocagene exuparvovec, an investigational gene therapy, are presented in this poster from the 2021 CNS Annual Meeting
Changes in cognition and language scale scores in children with AADC deficiency following treatment with eladocagene exuparvovec, an investigational gene therapy, are discussed in this poster from the 2021 CNS Annual Meeting
View the infographic distributed at our CNS 2020 symposium, which summarizes the differential diagnosis and management of AADC deficiency
View our symposium presentation at CNS 2020, which discusses making a differential diagnosis of AADC deficiency
View our virtual symposium presented at CNS 2020, which summarizes the characteristic clinical features of AADC deficiency
View the key takeaways from our CNS 2020 symposium, which summarizes the characteristic clinical features of aromatic L-amino acid decarboxylase (AADC) deficiency
Therapy area
Congress
Type
Topic
Year